Targeting IAP proteins for therapeutic intervention in cancer (original) (raw)

• Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
  Article CAS PubMed Google Scholar
• Fulda, S. Tumor resistance to apoptosis. Int. J. Cancer 124, 511–515 (2009).
  Article CAS PubMed Google Scholar
• Galluzzi, L. et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ. 19, 107–120 (2012).
  Article CAS PubMed Google Scholar
• Crook, N. E., Clem, R. J. & Miller, L. K. An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. J. Virol. 67, 2168–2174 (1993). This study identified the first viral iap gene from the Cydia pomonella granulovirus baculovirus.
  CAS PubMed PubMed Central Google Scholar
• Birnbaum, M. J., Clem, R. J. & Miller, L. K. An apoptosis-inhibiting gene from a nuclear polyhedrosis virus encoding a polypeptide with Cys/His sequence motifs. J. Virol. 68, 2521–2528 (1994).
  CAS PubMed PubMed Central Google Scholar
• Salvesen, G. S. & Duckett, C. S. IAP proteins: blocking the road to death's door. Nature Rev. Mol. Cell Biol. 3, 401–410 (2002).
  Article CAS Google Scholar
• Ndubaku, C., Cohen, F., Varfolomeev, E. & Vucic, D. Targeting inhibitor of apoptosis (IAP) proteins for therapeutic intervention. Future Med. Chem. 1, 1509–1525 (2009).
  Article CAS PubMed Google Scholar
• Vaux, D. L. & Silke, J. IAPs, RINGs and ubiquitylation. Nature Rev. Mol. Cell Biol. 6, 287–297 (2005).
  Article CAS Google Scholar
• Varfolomeev, E. & Vucic, D. (Un)expected roles of c-IAPs in apoptotic and NF-κB signaling pathways. Cell Cycle 7, 1511–1521 (2008).
  Article CAS PubMed Google Scholar
• Blankenship, J. W. et al. Ubiquitin binding modulates IAP antagonist-stimulated proteasomal degradation of c-IAP1 and c-IAP2. Biochem. J. 417, 149–160 (2009).
  Article CAS PubMed Google Scholar
• Gyrd-Hansen, M. et al. IAPs contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-κB as well as cell survival and oncogenesis. Nature Cell Biol. 10, 1309–1317 (2008).
  Article CAS PubMed Google Scholar
• Hauser, H. P., Bardroff, M., Pyrowolakis, G. & Jentsch, S. A giant ubiquitin-conjugating enzyme related to IAP apoptosis inhibitors. J. Cell Biol. 141, 1415–1422 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Chen, Z. et al. A human IAP-family gene, apollon, expressed in human brain cancer cells. Biochem. Biophys. Res. Commun. 264, 847–854 (1999).
  Article CAS PubMed Google Scholar
• Jeyaprakash, A. A. et al. Structure of a survivin–borealin–INCENP core complex reveals how chromosomal passengers travel together. Cell 131, 271–285 (2007).
  Article CAS PubMed Google Scholar
• Liston, P. et al. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature 379, 349–353 (1996).
  Article CAS PubMed Google Scholar
• Wilmanski, J. M., Petnicki-Ocwieja, T. & Kobayashi, K. S. NLR proteins: integral members of innate immunity and mediators of inflammatory diseases. J. Leukoc. Biol. 83, 13–30 (2008).
  Article CAS PubMed Google Scholar
• Altieri, D. C. Validating survivin as a cancer therapeutic target. Nature Rev. Cancer 3, 46–54 (2003).
  Article CAS Google Scholar
• Hunter, A. M., LaCasse, E. C. & Korneluk, R. G. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 12, 1543–1568 (2007).
  Article CAS PubMed Google Scholar
• Geddes, K., Magalhaes, J. G. & Girardin, S. E. Unleashing the therapeutic potential of NOD-like receptors. Nature Rev. Drug Discov. 8, 465–479 (2009).
  Article CAS Google Scholar
• Fulda, S. & Debatin, K. M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25, 4798–4811 (2006).
  Article CAS PubMed Google Scholar
• Ashkenazi, A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev. 19, 325–331 (2008).
  Article CAS PubMed Google Scholar
• Fulda, S., Galluzzi, L. & Kroemer, G. Targeting mitochondria for cancer therapy. Nature Rev. Drug Discov. 9, 447–464 (2010).
  Article CAS Google Scholar
• Chai, J. et al. Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature 406, 855–862 (2000).
  Article CAS PubMed Google Scholar
• Liu, Z. et al. Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. Nature 408, 1004–1008 (2000).
  Article CAS PubMed Google Scholar
• Wu, G. et al. Structural basis of IAP recognition by Smac/DIABLO. Nature 408, 1008–1012 (2000).
  Article CAS PubMed Google Scholar
• Adams, J. M. & Cory, S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26, 1324–1337 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Eckelman, B. P., Salvesen, G. S. & Scott, F. L. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep. 7, 988–994 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Srinivasula, S. M. et al. A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature 410, 112–116 (2001).
  Article CAS PubMed Google Scholar
• Shiozaki, E. N. et al. Mechanism of XIAP-mediated inhibition of caspase-9. Mol. Cell 11, 519–527 (2003).
  Article CAS PubMed Google Scholar
• Huang, Y. et al. Structural basis of caspase inhibition by XIAP: differential roles of the linker versus the BIR domain. Cell 104, 781–790 (2001).
  CAS PubMed Google Scholar
• Chai, J. et al. Structural basis of caspase-7 inhibition by XIAP. Cell 104, 769–780 (2001).
  Article CAS PubMed Google Scholar
• Riedl, S. J. et al. Structural basis for the inhibition of caspase-3 by XIAP. Cell 104, 791–800 (2001).
  Article CAS PubMed Google Scholar
• Silke, J. et al. Direct inhibition of caspase 3 is dispensable for the anti-apoptotic activity of XIAP. EMBO J. 20, 3114–3123 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Scott, F. L. et al. XIAP inhibits caspase-3 and -7 using two binding sites: evolutionarily conserved mechanism of IAPs. EMBO J. 24, 645–655 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Vucic, D. et al. Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor: implications for Smac-dependent anti-apoptotic activity of ML-IAP. Biochem. J. 385, 11–20 (2005).
  Article CAS PubMed Google Scholar
• Vucic, D., Dixit, V. M. & Wertz, I. E. Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death. Nature Rev. Mol. Cell Biol. 12, 439–452 (2011).
  Article CAS Google Scholar
• Hegde, R. et al. Identification of Omi/HtrA2 as a mitochondrial apoptotic serine protease that disrupts inhibitor of apoptosis protein-caspase interaction. J. Biol. Chem. 277, 432–438 (2002).
  Article CAS PubMed Google Scholar
• Verhagen, A. M. et al. HtrA2 promotes cell death through its serine protease activity and its ability to antagonize inhibitor of apoptosis proteins. J. Biol. Chem. 277, 445–454 (2002).
  Article CAS PubMed Google Scholar
• Martins, L. M. et al. The serine protease Omi/HtrA2 regulates apoptosis by binding XIAP through a reaper-like motif. J. Biol. Chem. 277, 439–444 (2002).
  Article CAS PubMed Google Scholar
• Suzuki, Y. et al. A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol. Cell 8, 613–621 (2001).
  Article CAS PubMed Google Scholar
• Liston, P. et al. Identification of XAF1 as an antagonist of XIAP anti-caspase activity. Nature Cell Biol. 3, 128–133 (2001).
  Article CAS PubMed Google Scholar
• Arora, V. et al. Degradation of survivin by the X-linked inhibitor of apoptosis (XIAP)–XAF1 complex. J. Biol. Chem. 282, 26202–26209 (2007).
  Article CAS PubMed Google Scholar
• Scheidereit, C. IκB kinase complexes: gateways to NF-κB activation and transcription. Oncogene 25, 6685–6705 (2006).
  Article CAS PubMed Google Scholar
• Bertrand, M. J. et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol. Cell 30, 689–700 (2008).
  Article CAS PubMed Google Scholar
• Varfolomeev, E. et al. c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor α (TNFα)-induced NF-κB activation. J. Biol. Chem. 283, 24295–24299 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Mahoney, D. J. et al. Both cIAP1 and cIAP2 regulate TNFα-mediated NF-κB activation. Proc. Natl Acad. Sci. USA 105, 11778–11783 (2008).
  Article PubMed PubMed Central Google Scholar
• Dynek, J. N. et al. c-IAP1 and UbcH5 promote K11-linked polyubiquitination of RIP1 in TNF signalling. EMBO J. 29, 4198–4209 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Haas, T. L. et al. Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. Mol. Cell 36, 831–844 (2009).
  Article CAS PubMed Google Scholar
• Varfolomeev, E. et al. Cellular inhibitors of apoptosis are global regulators of NF-κB and MAPK activation by TNF family receptors. Sci. Signal. (in the press).
• Tokunaga, F. et al. Involvement of linear polyubiquitylation of NEMO in NF-κB activation. Nature Cell Biol. 11, 123–132 (2009).
  Article CAS PubMed Google Scholar
• Gerlach, B. et al. Linear ubiquitination prevents inflammation and regulates immune signalling. Nature 471, 591–596 (2011).
  Article CAS PubMed Google Scholar
• Ikeda, F. et al. SHARPIN forms a linear ubiquitin ligase complex regulating NF-κB activity and apoptosis. Nature 471, 637–641 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Tokunaga, F. et al. SHARPIN is a component of the NF-κB-activating linear ubiquitin chain assembly complex. Nature 471, 633–636 (2011). The studies in REFS 50–53 identified Sharpin as a novel component of the linear ubiquitin chain assembly complex.
  Article CAS PubMed Google Scholar
• Keats, J. J. et al. Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma. Cancer Cell 12, 131–144 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Annunziata, C. M. et al. Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12, 115–130 (2007). The studies in REFS 54 and 55identified genetic abnormalities in several genes, including c-IAP proteins, of the canonical and non-canonical NF-κB pathways in multiple myeloma.
  Article CAS PubMed PubMed Central Google Scholar
• Grech, A. P. et al. TRAF2 differentially regulates the canonical and noncanonical pathways of NF-κB activation in mature B cells. Immunity 21, 629–642 (2004).
  Article CAS PubMed Google Scholar
• He, J. Q. et al. Rescue of TRAF3-null mice by p100 NF-κ B deficiency. J. Exp. Med. 203, 2413–2418 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Demchenko, Y. N. et al. Classical and/or alternative NF-κB pathway activation in multiple myeloma. Blood 115, 3541–3552 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Varfolomeev, E. et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-κB activation, and TNFα-dependent apoptosis. Cell 131, 669–681 (2007). This paper demonstrated that IAP antagonists induce apoptosis by triggering c-IAP1 degradation, NF-κB activation and autocrine TNF production, and identified c-IAP proteins as E3 ligases for NIK.
  Article CAS PubMed Google Scholar
• Vince, J. E. et al. IAP antagonists target cIAP1 to induce TNFα-dependent apoptosis. Cell 131, 682–693 (2007). This study demonstrated that IAP antagonists induce apoptosis by triggering c-IAP1 degradation, NF-κB activation and autocrine TNF production.
  Article CAS PubMed Google Scholar
• Vince, J. E. et al. TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1–TRAF2 complex to sensitize tumor cells to TNFα. J. Cell Biol. 182, 171–184 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Xiao, G., Harhaj, E. W. & Sun, S. C. NF-κB-inducing kinase regulates the processing of NF-κB2 p100. Mol. Cell 7, 401–409 (2001).
  Article CAS PubMed Google Scholar
• Senftleben, U. et al. Activation by IKKα of a second, evolutionary conserved, NF-κB signaling pathway. Science 293, 1495–1499 (2001).
  Article CAS PubMed Google Scholar
• Dejardin, E. The alternative NF-κB pathway from biochemistry to biology: pitfalls and promises for future drug development. Biochem. Pharmacol. 72, 1161–1179 (2006).
  Article CAS PubMed Google Scholar
• Imoto, I. et al. Identification of cIAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell carcinomas. Cancer Res. 61, 6629–6634 (2001).
  CAS PubMed Google Scholar
• Imoto, I. et al. Expression of cIAP1, a target for 11q22 amplification, correlates with resistance of cervical cancers to radiotherapy. Cancer Res. 62, 4860–4866 (2002).
  CAS PubMed Google Scholar
• Zender, L. et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125, 1253–1267 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Reardon, D. A. et al. Extensive genomic abnormalities in childhood medulloblastoma by comparative genomic hybridization. Cancer Res. 57, 4042–4047 (1997).
  CAS PubMed Google Scholar
• Weber, R. G., Sommer, C., Albert, F. K., Kiessling, M. & Cremer, T. Clinically distinct subgroups of glioblastoma multiforme studied by comparative genomic hybridization. Lab. Invest. 74, 108–119 (1996).
  CAS PubMed Google Scholar
• Dai, Z. et al. A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenes. Hum. Mol. Genet. 12, 791–801 (2003).
  Article CAS PubMed Google Scholar
• Bashyam, M. D. et al. Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer. Neoplasia 7, 556–562 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Ma, O. et al. MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression. Cancer Res. 69, 2559–2567 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Dierlamm, J. et al. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood 93, 3601–3609 (1999).
  CAS PubMed Google Scholar
• Akagi, T. et al. A novel gene, MALT1 at 18q21, is involved in t(11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. Oncogene 18, 5785–5794 (1999).
  CAS PubMed Google Scholar
• Zhou, H., Du, M. Q. & Dixit, V. M. Constitutive NF-kB activation by the t(11;18)(q21;q21) product in MALT lymphoma is linked to deregulated ubiquitin ligase activity. Cancer Cell 7, 425–431 (2005).
  Article CAS PubMed Google Scholar
• Morgan, J. A. et al. Breakpoints of the t(11;18)(q21;q21) in mucosa-associated lymphoid tissue (MALT) lymphoma lie within or near the previously undescribed gene MALT1 in chromosome 18. Cancer Res. 59, 6205–6213 (1999). The studies in REFS 74, 75 and 77 identified the t(11;18)(q21;q21) translocation and the corresponding c-IAP2–MALT1 fusion protein in MALT lymphoma.
  CAS PubMed Google Scholar
• Varfolomeev, E., Wayson, S. M., Dixit, V. M., Fairbrother, W. J. & Vucic, D. The inhibitor of apoptosis protein fusion c-IAP2•MALT1 stimulates NF-κB activation independently of TRAF1 AND TRAF2. J. Biol. Chem. 281, 29022–29029 (2006).
  Article CAS PubMed Google Scholar
• Waldele, K. et al. Requirement of the human T-cell leukemia virus (HTLV-1) tax-stimulated HIAP-1 gene for the survival of transformed lymphocytes. Blood 107, 4491–4499 (2006).
  Article CAS PubMed Google Scholar
• Tamm, I. et al. XIAP expression correlates with monocytic differentiation in adult de novo AML: impact on prognosis. Hematol. J. 5, 489–495 (2004).
  Article CAS PubMed Google Scholar
• Tamm, I. et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin. Cancer Res. 6, 1796–1803 (2000).
  CAS PubMed Google Scholar
• Carter, B. Z. et al. Caspase-independent cell death in AML: caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or survivin does not affect cell survival or prognosis. Blood 102, 4179–4186 (2003).
  Article CAS PubMed Google Scholar
• Hess, C. J. et al. Activated intrinsic apoptosis pathway is a key related prognostic parameter in acute myeloid leukemia. J. Clin. Oncol. 25, 1209–1215 (2007).
  Article CAS PubMed Google Scholar
• Tamm, I. et al. High expression levels of X-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clin. Cancer Res. 10, 3737–3744 (2004).
  Article CAS PubMed Google Scholar
• Sung, K. W. et al. Overexpression of X-linked inhibitor of apoptosis protein (XIAP) is an independent unfavorable prognostic factor in childhood de novo acute myeloid leukemia. J. Korean Med. Sci. 24, 605–613 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Hundsdoerfer, P., Dietrich, I., Schmelz, K., Eckert, C. & Henze, G. XIAP expression is post-transcriptionally upregulated in childhood ALL and is associated with glucocorticoid response in T-cell ALL. Pediatr. Blood Cancer 55, 260–266 (2010).
  Article PubMed Google Scholar
• Grzybowska-Izydorczyk, O., Cebula, B., Robak, T. & Smolewski, P. Expression and prognostic significance of the inhibitor of apoptosis protein (IAP) family and its antagonists in chronic lymphocytic leukaemia. Eur. J. Cancer 46, 800–810 (2010).
  Article CAS PubMed Google Scholar
• Vallat, L. et al. The resistance of B-CLL cells to DNA damage-induced apoptosis defined by DNA microarrays. Blood 101, 4598–4606 (2003).
  Article CAS PubMed Google Scholar
• Silva, K. L. et al. Apoptotic effect of fludarabine is independent of expression of IAPs in B-cell chronic lymphocytic leukemia. Apoptosis 11, 277–285 (2006).
  Article CAS PubMed Google Scholar
• Hussain, A. R. et al. Prognostic significance of XIAP expression in DLBCL and effect of its inhibition on AKT signalling. J. Pathol. 222, 180–190 (2010).
  Article CAS PubMed Google Scholar
• Ramp, U. et al. XIAP expression is an independent prognostic marker in clear-cell renal carcinomas. Hum. Pathol. 35, 1022–1028 (2004).
  Article CAS PubMed Google Scholar
• Yan, Y. et al. Disturbed balance of expression between XIAP and Smac/DIABLO during tumour progression in renal cell carcinomas. Br. J. Cancer 91, 1349–1357 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Mizutani, Y. et al. Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis. Int. J. Oncol. 30, 919–925 (2007).
  CAS PubMed Google Scholar
• Li, M., Song, T., Yin, Z. F. & Na, Y. Q. XIAP as a prognostic marker of early recurrence of nonmuscular invasive bladder cancer. Chin. Med. J. 120, 469–473 (2007).
  Article CAS PubMed Google Scholar
• Che, X. et al. Nuclear cIAP1 overexpression is a tumor stage- and grade-independent predictor of poor prognosis in human bladder cancer patients. Urol. Oncol. 25 Jul 2011 (doi:10.1016/j.urolonc.2010.12.016).
• Xiang, G., Wen, X., Wang, H., Chen, K. & Liu, H. Expression of X-linked inhibitor of apoptosis protein in human colorectal cancer and its correlation with prognosis. J. Surg. Oncol. 100, 708–712 (2009).
  Article CAS PubMed Google Scholar
• Krajewska, M. et al. Analysis of apoptosis protein expression in early-stage colorectal cancer suggests opportunities for new prognostic biomarkers. Clin. Cancer Res. 11, 5451–5461 (2005).
  Article CAS PubMed Google Scholar
• Esposito, I. et al. Overexpression of cellular inhibitor of apoptosis protein 2 is an early event in the progression of pancreatic cancer. J. Clin. Pathol. 60, 885–895 (2007).
  Article CAS PubMed Google Scholar
• Augello, C. et al. Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma. BMC Cancer 9, 125 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Shi, Y. H. et al. Expression of X-linked inhibitor-of-apoptosis protein in hepatocellular carcinoma promotes metastasis and tumor recurrence. Hepatology 48, 497–507 (2008).
  Article CAS PubMed Google Scholar
• Shibata, T. et al. Disturbed expression of the apoptosis regulators XIAP, XAF1, and Smac/DIABLO in gastric adenocarcinomas. Diagn. Mol. Pathol. 16, 1–8 (2007).
  Article CAS PubMed Google Scholar
• Seligson, D. B. et al. Expression of X-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence. Clin. Cancer Res. 13, 6056–6063 (2007).
  Article CAS PubMed Google Scholar
• Krajewska, M. et al. Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin. Cancer Res. 9, 4914–4925 (2003).
  CAS PubMed Google Scholar
• Zhang, Y. et al. X-linked inhibitor of apoptosis positive nuclear labeling: a new independent prognostic biomarker of breast invasive ductal carcinoma. Diagn. Pathol. 6, 49 (2011).
  Article PubMed PubMed Central Google Scholar
• Liu, S. S. et al. Anti-apoptotic proteins, apoptotic and proliferative parameters and their prognostic significance in cervical carcinoma. Eur. J. Cancer 37, 1104–1110 (2001).
  Article CAS PubMed Google Scholar
• Ferreira, C. G. et al. Expression of X-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patients. Clin. Cancer Res. 7, 2468–2474 (2001).
  CAS PubMed Google Scholar
• Ferreira, C. G. et al. Assessment of IAP (inhibitor of apoptosis) proteins as predictors of response to chemotherapy in advanced non-small-cell lung cancer patients. Ann. Oncol. 12, 799–805 (2001).
  Article CAS PubMed Google Scholar
• Hiscutt, E. L. et al. Targeting X-linked inhibitor of apoptosis protein to increase the efficacy of endoplasmic reticulum stress-induced apoptosis for melanoma therapy. J. Invest. Dermatol. 130, 2250–2258 (2010).
  Article CAS PubMed Google Scholar
• Qi, S. et al. Expression of cIAP-1 correlates with nodal metastasis in squamous cell carcinoma of the tongue. Int. J. Oral Maxillofac. Surg. 37, 1047–1053 (2008).
  Article CAS PubMed Google Scholar
• Tanimoto, T. et al. Nuclear expression of cIAP-1, an apoptosis inhibiting protein, predicts lymph node metastasis and poor patient prognosis in head and neck squamous cell carcinomas. Cancer Lett. 224, 141–151 (2005).
  Article CAS PubMed Google Scholar
• Vucic, D., Stennicke, H. R., Pisabarro, M. T., Salvesen, G. S. & Dixit, V. M. ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr. Biol. 10, 1359–1366 (2000).
  Article CAS PubMed Google Scholar
• Wagener, N. et al. Expression of inhibitor of apoptosis protein livin in renal cell carcinoma and non-tumorous adult kidney. Br. J. Cancer 97, 1271–1276 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Gong, J. et al. Melanoma inhibitor of apoptosis protein is expressed differentially in melanoma and melanocytic naevus, but similarly in primary and metastatic melanomas. J. Clin. Pathol. 58, 1081–1085 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Nachmias, B. et al. Caspase-mediated cleavage converts livin from an antiapoptotic to a proapoptotic factor: implications for drug-resistant melanoma. Cancer Res. 63, 6340–6349 (2003).
  CAS PubMed Google Scholar
• Dynek, J. N. et al. Microphthalmia-associated transcription factor is a critical transcriptional regulator of melanoma inhibitor of apoptosis in melanomas. Cancer Res. 68, 3124–3132 (2008).
  Article CAS PubMed Google Scholar
• Kempkensteffen, C. et al. Expression of the apoptosis inhibitor livin in renal cell carcinomas: correlations with pathology and outcome. Tumour Biol. 28, 132–138 (2007).
  Article CAS PubMed Google Scholar
• Haferkamp, A. et al. High nuclear livin expression is a favourable prognostic indicator in renal cell carcinoma. BJU Int. 102, 1700–1706 (2008).
  Article PubMed Google Scholar
• Gazzaniga, P. et al. Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer. Ann. Oncol. 14, 85–90 (2003).
  Article CAS PubMed Google Scholar
• Kempkensteffen, C. et al. Expression of splicing variants of the inhibitor of apoptosis livin in testicular germ cell tumors. Tumour Biol. 29, 76–82 (2008).
  Article CAS PubMed Google Scholar
• Wang, T. S. et al. Expression of livin in gastric cancer and induction of apoptosis in SGC-7901 cells by shRNA-mediated silencing of livin gene. Biomed. Pharmacother. 64, 333–338 (2010).
  Article CAS PubMed Google Scholar
• Choi, J. et al. Expression of livin, an antiapoptotic protein, is an independent favorable prognostic factor in childhood acute lymphoblastic leukemia. Blood 109, 471–477 (2007).
  Article CAS PubMed Google Scholar
• El-Mesallamy, H. O., Hegab, H. M. & Kamal, A. M. Expression of inhibitor of apoptosis protein (IAP) livin/BIRC7 in acute leukemia in adults: correlation with prognostic factors and outcome. Leuk. Res. 35, 1616–1622 (2011).
  Article CAS PubMed Google Scholar
• Nedelcu, T. et al. Livin and Bcl-2 expression in high-grade osteosarcoma. J. Cancer Res. Clin. Oncol. 134, 237–244 (2008).
  Article CAS PubMed Google Scholar
• Kim, D. K. et al. Expression of inhibitor-of-apoptosis protein (IAP) livin by neuroblastoma cells: correlation with prognostic factors and outcome. Pediatr. Dev. Pathol. 8, 621–629 (2005).
  Article CAS PubMed Google Scholar
• Mizutani, Y. et al. Downregulation of Smac/DIABLO expression in renal cell carcinoma and its prognostic significance. J. Clin. Oncol. 23, 448–454 (2005).
  Article CAS PubMed Google Scholar
• Kempkensteffen, C. et al. Expression levels of the mitochondrial IAP antagonists Smac/DIABLO and Omi/HtrA2 in clear-cell renal cell carcinomas and their prognostic value. J. Cancer Res. Clin. Oncol. 134, 543–550 (2008).
  Article CAS PubMed Google Scholar
• Mizutani, Y., Katsuoka, Y. & Bonavida, B. Prognostic significance of second mitochondria-derived activator of caspase (Smac/DIABLO) expression in bladder cancer and target for therapy. Int. J. Oncol. 37, 503–508 (2010).
  Article CAS PubMed Google Scholar
• Endo, K. et al. Clinical significance of Smac/DIABLO expression in colorectal cancer. Oncol. Rep. 21, 351–355 (2009).
  PubMed Google Scholar
• Yan, H. et al. Prognostic value of Smac expression in rectal cancer patients treated with neoadjuvant therapy. Med. Oncol. 25 Jan 2011 (doi:10.1007/s12032-011-9819-x).
• Pluta, P. et al. Correlation of Smac/DIABLO protein expression with the clinico-pathological features of breast cancer patients. Neoplasma 58, 430–435 (2011).
  Article CAS PubMed Google Scholar
• Dobrzycka, B. et al. Prognostic significance of smac/DIABLO in endometrioid endometrial cancer. Folia Histochem. Cytobiol. 48, 678–681 (2011).
  Article Google Scholar
• Arellano-Llamas, A. et al. High Smac/DIABLO expression is associated with early local recurrence of cervical cancer. BMC Cancer 6, 256 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Sekimura, A. et al. Expression of Smac/DIABLO is a novel prognostic marker in lung cancer. Oncol. Rep. 11, 797–802 (2004).
  CAS PubMed Google Scholar
• Pluta, A. et al. Influence of high expression of Smac/DIABLO protein on the clinical outcome in acute myeloid leukemia patients. Leuk. Res. 34, 1308–1313 (2010).
  Article CAS PubMed Google Scholar
• Vucic, D. & Fairbrother, W. J. The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin. Cancer Res. 13, 5995–6000 (2007).
  Article CAS PubMed Google Scholar
• Vucic, D., Kaiser, W. J., Harvey, A. J. & Miller, L. K. Inhibition of Reaper-induced apoptosis by interaction with inhibitor of apoptosis proteins (IAPs). Proc. Natl Acad. Sci. USA 94, 10183–10188 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Vucic, D., Kaiser, W. J. & Miller, L. K. Inhibitor of apoptosis proteins physically interact with and block apoptosis induced by Drosophila proteins HID and GRIM. Mol. Cell Biol. 18, 3300–3309 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Du, C., Fang, M., Li, Y., Li, L. & Wang, X. Smac, a mitochondrial protein that promotes cytochrome _c_-dependent caspase activation by eliminating IAP inhibition. Cell 102, 33–42 (2000).
  Article CAS PubMed Google Scholar
• Verhagen, A. M. et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 102, 43–53 (2000). The studies in REFS 138 and 139 identified the mitochondrial protein SMAC as a mammalian IAP antagonist that promotes caspase activation by neutralizing IAP proteins.
  Article CAS PubMed Google Scholar
• LaCasse, E. C. et al. IAP-targeted therapies for cancer. Oncogene 27, 6252–6275 (2008).
  Article CAS PubMed Google Scholar
• Franklin, M. C. et al. Structure and function analysis of peptide antagonists of melanoma inhibitor of apoptosis (ML-IAP). Biochemistry 42, 8223–8231 (2003).
  Article CAS PubMed Google Scholar
• Grether, M. E., Abrams, J. M., Agapite, J., White, K. & Steller, H. The head involution defective gene of Drosophila melanogaster functions in programmed cell death. Genes Dev. 9, 1694–1708 (1995).
  Article CAS PubMed Google Scholar
• Vucic, D. et al. SMAC negatively regulates the anti-apoptotic activity of melanoma inhibitor of apoptosis (ML-IAP). J. Biol. Chem. 277, 12275–12279 (2002). This was the first evidence that SMAC-mimicking peptides can sensitize cancer cells to chemotherapeutic agents.
  Article CAS PubMed Google Scholar
• Fulda, S., Wick, W., Weller, M. & Debatin, K. M. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nature Med. 8, 808–815 (2002). This was the first in vivo proof-of-concept study to show that antagonizing IAP proteins by a SMAC mimetic represents a promising strategy for sensitizing cancer cells to TRAIL-induced apoptosis.
  Article CAS PubMed Google Scholar
• Arnt, C. R., Chiorean, M. V., Heldebrant, M. P., Gores, G. J. & Kaufmann, S. H. Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J. Biol. Chem. 277, 44236–44243 (2002).
  Article CAS PubMed Google Scholar
• Yang, L. et al. Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide. Cancer Res. 63, 831–837 (2003).
  CAS PubMed Google Scholar
• Oost, T. K. et al. Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J. Med. Chem. 47, 4417–4426 (2004).
  Article CAS PubMed Google Scholar
• Sharma, S. K., Straub, C. & Zawel, L. Development of peptidomimetics targeting IAPs. Int. J. Pept. Res. Ther. 12, 21–32 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Kipp, R. A. et al. Molecular targeting of inhibitor of apoptosis proteins based on small molecule mimics of natural binding partners. Biochemistry 41, 7344–7349 (2002).
  Article CAS PubMed Google Scholar
• Flygare, J. A. & Fairbrother, W. J. Small-molecule pan-IAP antagonists: a patent review. Expert Opin. Ther. Pat. 20, 251–267 (2010).
  Article CAS PubMed Google Scholar
• Zobel, K. et al. Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs. ACS Chem. Biol. 1, 525–533 (2006).
  Article CAS PubMed Google Scholar
• Gaither, A. et al. A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-α signaling. Cancer Res. 67, 11493–11498 (2007).
  Article CAS PubMed Google Scholar
• Sun, H. et al. Design of small-molecule peptidic and nonpeptidic Smac mimetics. Acc. Chem. Res. 41, 1264–1277 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Cohen, F. et al. Orally bioavailable antagonists of inhibitor of apoptosis proteins based on an azabicyclooctane scaffold. J. Med. Chem. 52, 1723–1730 (2009).
  Article CAS PubMed Google Scholar
• Sun, H. et al. Structure-based design, synthesis, and evaluation of conformationally constrained mimetics of the second mitochondria-derived activator of caspase that target the X-linked inhibitor of apoptosis protein/caspase-9 interaction site. J. Med. Chem. 47, 4147–4150 (2004).
  Article CAS PubMed Google Scholar
• Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3–26 (2001).
  Article CAS PubMed Google Scholar
• Li, L. et al. A small molecule Smac mimic potentiates TRAIL- and TNFα-mediated cell death. Science 305, 1471–1474 (2004).
  Article CAS PubMed Google Scholar
• Sun, H. et al. Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. J. Am. Chem. Soc. 129, 15279–15294 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Petersen, S. L. et al. Autocrine TNFα signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 12, 445–456 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Gao, Z. et al. A dimeric Smac/diablo peptide directly relieves caspase-3 inhibition by XIAP. Dynamic and cooperative regulation of XIAP by Smac/Diablo. J. Biol. Chem. 282, 30718–30727 (2007).
  Article CAS PubMed Google Scholar
• Varfolomeev, E. et al. X chromosome-linked inhibitor of apoptosis regulates cell death induction by proapoptotic receptor agonists. J. Biol. Chem. 284, 34553–34560 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Jost, P. J. et al. XIAP discriminates between type I and type II FAS-induced apoptosis. Nature 460, 1035–1039 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Feltham, R. et al. Smac mimetics activate the E3 ligase activity of cIAP1 protein by promoting RING domain dimerization. J. Biol. Chem. 286, 17015–17028 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Mace, P. D. et al. Structures of the cIAP2 RING domain reveal conformational changes associated with ubiquitin-conjugating enzyme (E2) recruitment. J. Biol. Chem. 283, 31633–31640 (2008).
  Article CAS PubMed Google Scholar
• Dueber, E. C. et al. Antagonists induce a conformational change in cIAP1 that promotes autoubiquitination. Science 334, 376–380 (2011).
  Article CAS PubMed Google Scholar
• Ndubaku, C. et al. Antagonism of c-IAP and XIAP proteins is required for efficient induction of cell death by small-molecule IAP antagonists. ACS Chem. Biol. 4, 557–566 (2009).
  Article CAS PubMed Google Scholar
• Schimmer, A. D., Dalili, S., Batey, R. A. & Riedl, S. J. Targeting XIAP for the treatment of malignancy. Cell Death Differ. 13, 179–188 (2006).
  Article CAS PubMed Google Scholar
• Wu, T. Y., Wagner, K. W., Bursulaya, B., Schultz, P. G. & Deveraux, Q. L. Development and characterization of nonpeptidic small molecule inhibitors of the XIAP/caspase-3 interaction. Chem. Biol. 10, 759–767 (2003).
  Article CAS PubMed Google Scholar
• Schimmer, A. D. et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 5, 25–35 (2004).
  Article CAS PubMed Google Scholar
• Gonzalez-Lopez, M. et al. Design, synthesis and evaluation of monovalent Smac mimetics that bind to the BIR2 domain of the anti-apoptotic protein XIAP. Bioorg. Med. Chem. Lett. 21, 4332–4336 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Jansen, B. & Zangemeister-Wittke, U. Antisense therapy for cancer — the time of truth. Lancet Oncol. 3, 672–683 (2002).
  Article CAS PubMed Google Scholar
• LaCasse, E. C. et al. Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Clin. Cancer Res. 12, 5231–5241 (2006).
  Article CAS PubMed Google Scholar
• Shaw, T. J., Lacasse, E. C., Durkin, J. P. & Vanderhyden, B. C. Downregulation of XIAP expression in ovarian cancer cells induces cell death in vitro and in vivo. Int. J. Cancer 122, 1430–1434 (2008).
  Article CAS PubMed Google Scholar
• Cao, C., Mu, Y., Hallahan, D. E. & Lu, B. XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene 23, 7047–7052 (2004).
  Article CAS PubMed Google Scholar
• McManus, D. C. et al. Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene 23, 8105–8117 (2004).
  Article CAS PubMed Google Scholar
• Holt, S. V., Brookes, K. E., Dive, C. & Makin, G. W. Down-regulation of XIAP by AEG35156 in paediatric tumour cells induces apoptosis and sensitises cells to cytotoxic agents. Oncol. Rep. 25, 1177–1181 (2011).
  CAS PubMed Google Scholar
• Hu, Y. et al. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin. Cancer Res. 9, 2826–2836 (2003).
  CAS PubMed Google Scholar
• Amantana, A., London, C. A., Iversen, P. L. & Devi, G. R. X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. Mol. Cancer Ther. 3, 699–707 (2004).
  CAS PubMed Google Scholar
• Dean, E. et al. Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer. J. Clin. Oncol. 27, 1660–1666 (2009).
  Article CAS PubMed Google Scholar
• Schimmer, A. D. et al. PhaseI/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. J. Clin. Oncol. 27, 4741–4746 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Carter, B. Z. et al. XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38− cells in a Phase 1/2 study of patients with relapsed/refractory AML. Apoptosis 16, 67–74 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Schimmer, A. D. et al. Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized Phase II study. Clin. Lymphoma Myeloma Leuk. 11, 433–438 (2011).
  Article CAS PubMed Google Scholar
• Stadel, D. et al. Requirement of NF-κB for Smac mimetic-mediated sensitization of pancreatic carcinoma cells for gemcitabine-induced apoptosis. Neoplasia (in the press).
• Cheng, Y. J. et al. XIAP-mediated protection of H460 lung cancer cells against cisplatin. Eur. J. Pharmacol. 627, 75–84 (2010).
  Article CAS PubMed Google Scholar
• Loeder, S. et al. RIP is required for IAP inhibitor-mediated sensitization of childhood acute leukemia cells to chemotherapy-induced apoptosis. Leukemia (in the press).
• Carter, B. Z. et al. Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells. Blood 105, 4043–4050 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Dean, E. J. et al. A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC. Br. J. Cancer 102, 97–103 (2010).
  Article CAS PubMed Google Scholar
• Probst, B. L. et al. Smac mimetics increase cancer cell response to chemotherapeutics in a TNF-α-dependent manner. Cell Death Differ. 17, 1645–1654 (2010).
  Article CAS PubMed Google Scholar
• Bockbrader, K. M., Tan, M. & Sun, Y. A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells. Oncogene 24, 7381–7388 (2005).
  Article CAS PubMed Google Scholar
• Metwalli, A. R. et al. Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells. Cancer Biol. Ther. 10, 885–892 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Chauhan, D. et al. Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood 109, 1220–1227 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Guo, F. et al. Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/diablo) or cotreatment with N-terminus of Smac/diablo peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis. Blood 99, 3419–3426 (2002).
  Article CAS PubMed Google Scholar
• Ziegler, D. S. et al. A small-molecule IAP inhibitor overcomes resistance to cytotoxic therapies in malignant gliomas in vitro and in vivo. Neuro Oncol. 13, 820–829 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Servida, F. et al. Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptor-mediated apoptosis. Invest. New Drugs 29, 1264–1275 (2011).
  Article CAS PubMed Google Scholar
• Dineen, S. P. et al. Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer. Cancer Res. 70, 2852–2861 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Fandy, T. E., Shankar, S. & Srivastava, R. K. Smac/DIABLO enhances the therapeutic potential of chemotherapeutic drugs and irradiation, and sensitizes TRAIL-resistant breast cancer cells. Mol. Cancer 7, 60 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Fingas, C. D. et al. A Smac mimetic reduces TNF related apoptosis inducing ligand (TRAIL)-induced invasion and metastasis of cholangiocarcinoma cells. Hepatology 52, 550–561 (2010).
  Article CAS PubMed Google Scholar
• Crnkovic-Mertens, I., Hoppe-Seyler, F. & Butz, K. Induction of apoptosis in tumor cells by siRNA-mediated silencing of the livin/ML-IAP/KIAP gene. Oncogene 22, 8330–8336 (2003).
  Article CAS PubMed Google Scholar
• Lecis, D. et al. Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and bortezomib. Br. J. Cancer 102, 1707–1716 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Dai, Y. et al. A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-κB. BMC Cancer 9, 392 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Cheung, H. H., Mahoney, D. J., Lacasse, E. C. & Korneluk, R. G. Down-regulation of c-FLIP enhances death of cancer cells by Smac mimetic compound. Cancer Res. 69, 7729–7738 (2009).
  Article CAS PubMed Google Scholar
• Ren, X., Xu, Z., Myers, J. N. & Wu, X. Bypass NFκB-mediated survival pathways by TRAIL and Smac. Cancer Biol. Ther. 6, 1031–1035 (2007).
  Article CAS PubMed Google Scholar
• Petrucci, E. et al. A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells. Gynecol. Oncol. 105, 481–492 (2007).
  Article CAS PubMed Google Scholar
• Frenzel, L. P. et al. Novel X-linked inhibitor of apoptosis inhibiting compound as sensitizer for TRAIL-mediated apoptosis in chronic lymphocytic leukaemia with poor prognosis. Br. J. Haematol. 152, 191–200 (2011).
  Article CAS PubMed Google Scholar
• Stadel, D. et al. TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors. Clin. Cancer Res. 16, 5734–5749 (2010).
  Article CAS PubMed Google Scholar
• Siegelin, M. D., Gaiser, T. & Siegelin, Y. The XIAP inhibitor embelin enhances TRAIL-mediated apoptosis in malignant glioma cells by down-regulation of the short isoform of FLIP. Neurochem. Int. 55, 423–430 (2009).
  Article CAS PubMed Google Scholar
• Haag, C. et al. Identification of c-FLIPL and c-FLIPS as critical regulators of death receptor-induced apoptosis in pancreatic cancer cells. Gut 60, 225–237 (2011).
  Article CAS PubMed Google Scholar
• Kater, A. P. et al. Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis. Blood 106, 1742–1748 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Lu, J. et al. Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment. Mol. Cancer Ther. 10, 902–914 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Mori, T. et al. Effect of the XIAP inhibitor embelin on TRAIL-induced apoptosis of pancreatic cancer cells. J. Surg. Res. 142, 281–286 (2007).
  Article CAS PubMed Google Scholar
• Loeder, S. et al. A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia. Cancer Res. 69, 8977–8986 (2009).
  Article CAS PubMed Google Scholar
• Vogler, M. et al. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res. 69, 2425–2434 (2009).
  Article CAS PubMed Google Scholar
• Loeder, S., Drensek, A., Jeremias, I., Debatin, K. M. & Fulda, S. Small molecule XIAP inhibitors sensitize childhood acute leukemia cells for CD95-induced apoptosis. Int. J. Cancer 126, 2216–2228 (2010).
  CAS PubMed Google Scholar
• Geserick, P. et al. Cellular IAPs inhibit a cryptic CD95-induced cell death by limiting RIP1 kinase recruitment. J. Cell Biol. 187, 1037–1054 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Wang, L., Du, F. & Wang, X. TNF-α induces two distinct caspase-8 activation pathways. Cell 133, 693–703 (2008).
  Article CAS PubMed Google Scholar
• Laukens, B. et al. Smac mimetic bypasses apoptosis resistance in FADD- or caspase-8-deficient cells by priming for tumor necrosis factor α-induced necroptosis. Neoplasia 13, 971–979 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Vanlangenakker, N. et al. cIAP1 and TAK1 protect cells from TNF-induced necrosis by preventing RIP1/RIP3-dependent reactive oxygen species production. Cell Death Differ. 18, 656–665 (2011).
  Article CAS PubMed Google Scholar
• Vellanki, S. H. et al. Small-molecule XIAP inhibitors enhance γ-irradiation-induced apoptosis in glioblastoma. Neoplasia 11, 743–752 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Giagkousiklidis, S., Vellanki, S. H., Debatin, K. M. & Fulda, S. Sensitization of pancreatic carcinoma cells for γ-irradiation-induced apoptosis by XIAP inhibition. Oncogene 26, 7006–7016 (2007).
  Article CAS PubMed Google Scholar
• Dai, Y. et al. Natural IAP inhibitor embelin enhances therapeutic efficacy of ionizing radiation in prostate cancer. Am. J. Cancer Res. 1, 128–143 (2011).
  CAS PubMed Google Scholar
• Dai, Y. et al. Molecularly targeted radiosensitization of human prostate cancer by modulating inhibitor of apoptosis. Clin. Cancer Res. 14, 7701–7710 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Berger, R. et al. NF-κB is required for Smac mimetic-mediated sensitization of glioblastoma cells for γ-irradiation-induced apoptosis. Mol. Cancer Ther. 10, 1867–1875 (2011).
  Article CAS PubMed Google Scholar
• Weisberg, E. et al. Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells. Mol. Cancer Ther. 6, 1951–1961 (2007).
  Article CAS PubMed Google Scholar
• Ziegler, D. S. et al. Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins. J. Clin. Invest. 118, 3109–3122 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Foster, F. M. et al. Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer. Breast Cancer Res. 11, R41 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Weisberg, E. et al. Smac mimetics: implications for enhancement of targeted therapies in leukemia. Leukemia 24, 2100–2109 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Aird, K. M., Ghanayem, R. B., Peplinski, S., Lyerly, H. K. & Devi, G. R. X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor. Mol. Cancer Ther. 9, 1432–1442 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Weisberg, E. et al. Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML. Leukemia 24, 1375–1378 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Infante, J. R. et al. A Phase I study of LCL-161, an oral IAP inhibitor, in patients with advanced cancer. in: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research (17–21 Apr 2010; Washington DC, USA; Abstract 2775).
• Amaravadi, R. K. et al. Phase 1 study of the Smac mimetic TL32711 in adult subjects with advanced solid tumors and lymphoma to evaluate safety, pharmacokinetics, pharmacodynamics and antitumor activity. in: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research (2–6 Apr 2011; Orlando, Florida; Abstract LB-406).
• Sikic, B. I. et al. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advanced solid tumors: Results of a phase I study. J. Clin. Oncol. (Meeting Abstracts) 29, 3008 (2011).
  Article Google Scholar
• Dougan, M. et al. IAP inhibitors enhance co-stimulation to promote tumor immunity. J. Exp. Med. 207, 2195–2206 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Hinds, M. G., Norton, R. S., Vaux, D. L. & Day, C. L. Solution structure of a baculoviral inhibitor of apoptosis (IAP) repeat. Nature Struct. Biol. 6, 648–651 (1999).
  Article CAS PubMed Google Scholar
• Sun, C. et al. NMR structure and mutagenesis of the inhibitor-of-apoptosis protein XIAP. Nature 401, 818–822 (1999).
  Article CAS PubMed Google Scholar
• Cai, Q. et al. A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. J. Med. Chem. 54, 2714–2726 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Larisch, S. et al. A novel mitochondrial septin-like protein, ARTS, mediates apoptosis dependent on its P-loop motif. Nature Cell Biol. 2, 915–921 (2000).
  Article CAS PubMed Google Scholar